Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.90, read 2026-11-01
Ethical does not pass the values gate
Price8.14 USD
Fair value8.75
Ethical score70.0/100
Value readFairas of 3 Nov 2026
Our investment reviews on this name
2026-11-03Read Markup8.20-0.7% to today Accumulation gives way to Markup after a 36% rise in 3 weeks
2026-10-13Read Accumulation6.04+34.8% to today ✓Markdown gives way to Accumulation after a 7% rise in 11 days
2026-10-02Read Markdown5.64+44.3% to today Markup gives way to Markdown after a 9% slide in 6 weeks
2026-08-23Read Markup6.21+31.1% to today ✓Markdown gives way to Markup after a 23% rise in 7 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Bausch Health Companies Inc. holds its Markup at $8.14. The statistical read favours the sellers, held for 1 days.
As held on the ledger · 2026-11-03
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 1 days
Price at the screen
$8.14
Valuation
N/A trailing · 1.51 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.37
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
79.08%
Below 33%
Interest-bearing debt is 79.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
13.88%
Below 49%
Money owed to the company is 13.9% of assets, under the 49% limit.
Pass
Revenue purity
0.47%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Bausch Health Companies's business is in a permissible area, but its interest-bearing debt is about 79% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BHC's ethical verdict changes
Today BHC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades at roughly an 8% discount to our $8.75 fair value, 12.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 7.0% discount to the base estimate.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Canada and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BHC trades on the NYSE (the company is based in Canada). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup · changed$8.20+26.3%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 26.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-10-27Accumulation$6.49+2.9%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-10-20Accumulation$6.31+4.5%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-10-13Accumulation · changed$6.04+7.1%Entry 7
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-10-02Markdown · changed$5.64-9.2%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-08-23Markup · changed$6.21+28.6%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 28.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-07-23Markdown$4.83-4.5%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-07-18Markdown$5.06+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it hold, with a mean price target of $8.
2026-07-03Markdown$5.06+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$5.06Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.